Earnings ·
Alvotech reported a net loss of $65.8 million for the six months ended June 30, 2026, compared to a net profit of…
ALVOWAlvotech
Alvotech reported a net loss of $65.8 million for the six months ended June 30, 2026, compared to a net profit of $141.7 million in the prior-year period. Product revenue declined 48% to $105.9 million due to manufacturing disruptions following an FDA inspection, while license and milestone revenue rose 4.4% to $105.7 million. The company completed an equity financing in June 2026 generating gross proceeds of $164.6 million and secured a $75.0 million financing facility. General and administrative expenses increased to $69.2 million, largely driven by a $20.2 million provision for commercial matters. Alvotech operates as a biopharmaceutical company specializing in the development and manufacturing of biosimilar medicines.